[acute Exposure To Imidazoline Derivatives In Children]. by Bucaretchi, Fábio et al.




Copyright © 2003 by Sociedade Brasileira de Pediatria
ORIGINAL ARTICLE
1. PhD. Assistant professor, Department of Pediatrics, School of Medicine,
Universidade Estadual de Campinas (UNICAMP), Campinas, SP, Brazil.
2. Medical student, School of Medicine, Universidade Estadual de Campinas
(UNICAMP), Campinas, SP, Brazil.
3. PhD. Assistant professor, Department of Medical Practice, School of
Medicine, Universidade Estadual de Campinas (UNICAMP), Campinas,
SP, Brazil.
Manuscript received May 28 2003, accepted for publication Aug 26 2003.
Abstract
Objectives: To study acute exposure to imidazoline derivatives in 72 children younger than 15 years
of age, followed-up from January 1994 to December 1999.
Method: This is a retrospective study of 72 patients with age between 2 months and 13 years (median
2 years; 25-75% = 1 to 3 years old) exposed to naphazoline (N = 48), fenoxazoline (N = 18), oxymetazoline
(N = 5) and tetrahydrozoline (N = 1), through oral (N = 46), nasal (N = 24) or unknown (N = 2) routes.
Results: Fifty-seven children developed clinical manifestations such as somnolence (N= 34/57),
sweating (N = 20/57), pallor (N = 17/57), hypothermia (N = 16/57), bradycardia (N=13/57), cool
extremities (N = 9/57), restlessness (N = 7/57), tachycardia (N = 6/57), vomiting (N= 5/57), irregular
respiratory pattern and apnea (N = 5/57), miosis/mydriasis (N = 4/57). Naphazoline was the active
ingredient most frequently involved (N = 47), followed by fenoxazoline (N = 5) and oxymetazoline (N =
4). The onset of clinical manifestations was rapid, beginning within 2 hours after exposure in 32/57
children. Only supportive measures were employed, with one child requiring mechanical ventilation after
accidental naphazoline ingestion. In most of the children resolution of symptoms occurred within 24 hours
(N = 39/57). No deaths were observed. Patients exposed to naphazoline (N = 47/48) presented a higher
frequency of clinical signs of poisoning in comparison with those exposed to fenoxazoline (N = 5/18) (p
< 0.001). There were no significant differences in the frequency of patients who presented clinical
manifestations considering the route of exposure [oral (N = 34/46), nasal (N = 21/24); p = 0.31].
Conclusion: Most children (especially those younger than 3 years) exposed to imidazoline derivatives
(especially naphazoline) presented early signs of poisoning regardless of the exposure route (nasal or oral).
The main signs observed were nervous system, cardiovascular and respiratory depression. Most children
showed complete resolution of the symptoms within 24 hours.
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Introduction
Imidazoline derivatives are often employed as topical
nasal and ocular decongestants, with rapid and prolonged
action.1-6 Its therapeutic action results from stimulation of
the peripheral post-synaptic a2-adrenergic receptors of the
mucosa, causing local vasoconstriction and, eventually
520  Jornal de Pediatria - Vol. 79, Nº6, 2003
systemic vasoconstriction and it may cause transitory arterial
hypertension, pallor and diaphoresis.1-5,7-10 Imidazoline
derivatives can also stimulate post-synaptic α2-adrenergic
receptors at cardiovascular and central nervous system
control centers, causing inhibition of cerebral sympathetic
outflow.5,7-9 In such situations patients, primarily children,
may present bradycardia, arterial hypotension and
neurological and respiratory depression resulting from toxic
or “therapeutic” doses.1,5,7,9-16
According to data from the National Agency for Sanitary
Vigilance (ANVISA- Agência Nacional de Vigilância
Sanitária, May 2003), the main imidazoline derivatives
found on the Brazilian market in the form of topical
decongestants are naphazoline (59 products registered),
oxymetazoline (15 products registered), fenoxazoline (nine
products registered), tetrahydrozoline (eight products
registered) and xylometazoline (four products registered).
These products are indicated for symptomatic relief of
acute conjunctivitis, rhinitis and/or adenoiditis, having little
or no effect on chronic rhinitis and sinusitis or on vasomotor
rhinitis.1,3-7 The decongestant action begins after around 5
to 10 minutes, and the duration of the therapeutic effects of
naphazoline and fenoxazoline varies from 3 to 6 hours,
while for oxymetazoline it can be from 6 to 12 hours.2,4,6
Continuous use of these medications for a few days can
cause uncomfortable congestive rebound effects and
rhinorrhea.2,4,6  Despite the widespread use of these drugs
and the potential risks of their use with children there is no
consensus on their posology or the duration of treatment
and they can be obtained without medical
prescriptions.1,5,7,9-11
Based on these observations, the objective of this
study was to perform a retrospective analysis of cases of
acute exposure to imidazoline derivatives in children
aged less than 15 years, followed by the Poison Control
Center at the Medical Sciences Faculty of UNICAMP
(CCI-FCM-UNICAMP), during the period between
January 1994 and December 1999.
Methods
Medical records of patients followed by CCI-FCM-
UNICAMP were selected by searching the center’s
database, using the following keywords: imidazoline
derivatives, age less than 15 years and period between
January 1994 and December 1999. The information
contained in the medical records was checked by two
observers and the following variables extracted to fill out
the study protocol: age, sex, commercial name of the
product involved, active ingredient and concentration,
time interval between exposure and attendance at the
CCI, exposure route, signs and symptoms observed,
period of symptom remission, treatment employed and
progress. In order to analyze the distribution of variable
frequency a new database was created using Epi-Info
6.04 (CDC, Atlanta, GA, USA).
One hundred and four cases were analyzed, of which
72 were selected for the study. The criterion for inclusion
was that all variables to be analyzed were present on the
protocol, including monitoring of the patient until
complete recovery from the clinical condition. The
difference in frequency between given variables was
compared using the chi-square test and Fisher’s exact
test. Values of p < 0.05 were considered to represent
statistical significance. The project was approved by the
Committee for Ethics in Research of FCM-UNICAMP,
hearing 461/2001.
Results
The age of the 72 children treated varied from 2
months to 12 years, with a median of 21 months (25-75%
= 12-36 months) and a mean of 26 + 23 months and
51.4% were female. In 46 cases exposure was via the oral
route, via nasal in 24 and unknown in two cases. The
median of time passed between exposure and first contact
with the CCI was 2 hours (25-75% = 1 to 5 hours).
The brand names and active ingredients employed in
the 72 cases are listed in Table 1, with products containing
naphazoline as the active ingredient highlighted.
Of the 72 patients studied, 15 remained asymptomatic,
the majority exposed to fenoxazoline (N = 13, Table 2).
Comparing the frequency of symptomatic and
asymptomatic patients according to the active ingredients
naphazoline and fenoxazoline, it will be observed that
patients exposed to naphazoline presented a greater risk
of exhibiting clinical manifestations indicative of
intoxication [Table 2; naphazoline (47/48) vs.
fenoxazoline (5/18); Fisher’s exact test, p < 0.001].
When considering the route of exposure in terms of the
presence or absence of clinical manifestations [oral (N =
34/46) vs. nasal (N = 21/24)], the difference is not
statistically significant (Table 3; chi-square test, p =
0.31).
Of the 57 patients that presented cl inical
manifestations, the great majority had been exposed to
naphazoline (Table 2), with somnolence, diaphoresis,
pallor, hypothermia and bradycardia the most common
(Table 4). Only one patient, one year old, who had
ingested a bottle of Sorine adulto® (naphazoline at
0.05%), required mechanical ventilation and was
discharged from hospital in 3 days. The majority of the
patients (68.4%) were asymptomatic 24 hours after
exposure. There were no deaths.
Although the information on case development and
outcome was incomplete for the excluded group (N =
32), this group was no different from the study group in
terms of demographic characteristics and variables
analyzed: age group (median = 20 months, 25-75% = 7 to
36 months); gender [female (N = 18), male (N = 13), not
recorded (N = 1)]; interval, in hours, between exposure
Acute exposure to imidazoline derivatives in children – Bucaretchi F et alii
Jornal de Pediatria - Vol. 79, Nº6, 2003  521
and attendance at the center (median = 2 hours, 25-75%
= 1 to 5 hours); exposure route [nasal (N = 13), oral (N
= 18), not recorded (N = 1)] and active ingredients
involved [naphazoline (N = 26), fenoxazoline (N = 5)
and oxymetazoline (1)].
Discussion
Imidazoline derivatives have been widely used since the
1940s, when naphazoline was launched on the
pharmaceutical market.2,4,11,14 Since then, sporadic works,
Table 1 - Brand names, active ingredient and concentration of imidazoline derivates involved
in 72 cases of acute exposure in children
Brand name Active ingredient Concentration (%) n %
Multigen-AL® naphazoline 0.05 20 27.8
Aturgyl® fenoxazoline 0.05* - 0.1 18 25.0
Sorine adulto® naphazoline 0.05 13 18.1
Naridrin® naphazoline 0.05* - 0.1 8 11.1
Afrin® oxymetazoline 0.025* - 0.05 5 6.9
Privina® naphazoline 0.05 2 2.8
Nazobio® naphazoline 0.05 1 1.4
Lerin® naphazoline 0.05 1 1.4
Visodin® tetrahydrozoline 0.05 1 1.4
Non mentioned naphazoline  3 4.2
Total  72 100.0
* Concentration of the active ingredient in preparations for pediatric use.
Table 2 - Comparison between the groups of asymptomatic
and symptomatic patients among 72 children with
acute exposure to imidazoline derivates according to
the active ingredient
Active ingredient Symptomatic Asymptomatic Total
Naphazoline 47 1 48
Fenoxazoline 5 13 18
Oxymetazoline 4 1 5
Tetrahydrozoline 1 0 1
Total 57 15 72
Table 3 - Main routes of exposure to imidazoline derivates
among 57 children who presented clinical
manifestations of toxicity according to the active
ingredient
Active ingredient Oral Nasal Unknown Total
Naphazoline 28 18 1 47
Fenoxazoline 4 1 0 5
Oxymetazoline 2 2 0 4
Tetrahydrozoline 0 0 1 1
Total 34 21 2 57
the majority in the form of isolated case reports, have
warned of the risks of the indiscriminate use of these drugs,
primarily with children less than 2 years old.5,7,9-14,16
Among papers published since 1970, only three studies
described clinical series of patients exposed to imidazoline
derivatives,9-11 the results of which were similar to those
described for the current series, highlighting neurological,
cardiovascular and respiratory manifestations (Table 4). Of
the 64 cases described by Bruni,11 74.9% occurred among
children less than 2 years old. Mahieu et al.9 nalyzed 261
cases of exposure to imidazoline derivatives followed by
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the Belgian Poison Control Centre, from 1986 to 1991,
describing a more detailed analysis of 19 children. Of the
261 cases, 89.6% were children less than 4 years old, 75%
due to accidental ingestion 25% after “therapeutic” use as
nasal topicals (24%) or eye drops (1%).
The time passed between exposure and first contact with
the CCI was less than 2 hours in 56.3% of the 72 patients.
This is due to the rapid absorption of imidazoline derivatives,
resulting in the early appearance of clinical
manifestations.2,4,6 Fifty of the 72 children exposed to
imidazolines were less than 2 years old, representing 7% of
all patients exposed to medications within this age group (N
= 50/719), followed by the CCI during the period studied
(1994-1999).
Of the 57 symptomatic patients, oral (N = 34) and nasal
(N = 21) routes were the most common. Multigen-AL® was
the main commercial product involved in naphazoline
exposure (N = 20/48) and all of the children who had been
exposed to this product developed clinical manifestations.
Despite the nonexistence of any indications for imidazoline
derivatives administered sub-lingually as systemic
decongestants,2,4,6 naphazoline (0.05%) is contained in
this formulation associated with a pool of antigens, employed
for “desensitization” of atopical patients via this route. The
other patients exposed to imidazoline derivatives via oral
route, and who presented clinical manifestations, must have
been the result of accidental use. In respect of symptomatic
patients exposed via nasal route, it is presumed that these
manifestations were the result of toxic effects from
indiscriminate use or from adverse effects. Commercial
formulations for pediatric use contain, in general, half the
concentration of those for adults1,4,7 (Table 1). Taking the
body surface area of RN and infants into account, these age
groups may be being exposed to potentially toxic doses of
these medications.
Pharmacology texts, from the British Pharmacopoeia
and on treatment, during the 70s and 80s were already
warning of the risks of using topical decongestants with
children.2,4,6 According to Schvartsman,6 naphazoline
should not be used with children less than six years old. This
author recommends the use of oxymetazoline or
xylometazoline as topical nasal decongestants for children
between 2 and six years of age, and does not indicate any of
these drugs for the under two years age group. In the data
analyzed here, it was found that 47/48 of those exposed to
naphazoline developed clinical manifestations, including
cases where usage was topical and nasal (18 children, Table
3), while 13/18 of those exposed to fenoxazoline remained
asymptomatic. This data indicates that topical fenoxazoline
use for children may, perhaps, be safer than with naphazoline
(Table 2).
Although there is no specific treatment, naloxone has
been suggested as a possible antagonist7,9,15 and is often
employed in cases of intoxication by clonidine,17-21 an
α2-agonist drug derived from imidazoline used as a
centrally acting anti-hypertension agent.8,17-19 As it is
opioid-like, clonidine has been indicated for the treatment
of patients who are dependent on opioid drugs.8,17-20
Intoxication by clonidine causes similar clinical
manifestations to those produced by other imidazoline
derivatives.17-21 however there are no controlled trials
proving the efficacy of naloxone in cases of intoxication














Table 4 - Clinical manifestations of intoxication presented by 57 children after acute
exposure to imidazoline derivatives
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by topical decongestants. According to the literature
consulted, naloxone was employed for just one fifteen-
month old patient who had been exposed to
oxymetazoline, without success.9
Once an hour has passed after ingestion, gastric
lavage is no longer recommendable due to the rapid rate
of absorption and the central neural depressive effect ,
increasing aspiration risks.5,7,9,22 An isolated dose of
activated charcoal may be of use up to one hour after
ingestion, but the risk of aspiration is still present.5,7,9,23
Despite these risks, a single dose of activated charcoal
(N = 21) and gastric lavage (N = 14) were used with
symptomatic children and there is no record of aspiration
in any of the patients. Treatment of the clinical
manifestations is basically symptomatic and supportive,
including mechanical ventilation for patients with severe
respiratory depression, while the use of atropine is
questionable,5,7,9 but was used with one patient in this
series. Remission of the symptoms generally occurs in 24
to 36 hours.1,5,7,9-14,16 In the current series, mechanical
ventilation was employed in just one case and 68.4% of
the patients were asymptomatic 24 hours after exposure.
Although 32 cases were excluded, the data from this
group suggest that their removal will not have interfered
with the results presented by the study group, indicating
that there should not have been selection bias.
Within the methodological limits of a retrospective,
it can be concluded that acute exposure to imidazoline
derivatives, particularly to naphazoline and in children
less than three years old, causes, in the majority of cases,
irrespective of the exposure route (oral or nasal), the
rapid appearance of cl inical manifestations of
intoxication, of which neurological, cardiovascular and
respiratory depression stand out. These manifestations
abate, in general within 24 hours of exposure. It can also
be inferred that products containing these active
ingredients should be indicated with great caution for
this age group, calling particular attention to the risks of
administering Multigen-AL®.
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